THE EFFICIENCY OF USING THE MEDICATION COMBING 150 MG OF ISONIAZID , 375 MG OF PYRAZINA MIDE , 150 MG OF RI FAMPICIN IN THE TREATMEN T OF RESPIRATOR Y TUBERCULOSIS IN CHILDREN

The main problem for treatment of children with various manifestations of tuberculosis is the lack of pediatric dosages of anti-tuberculosis drugs. Considering the current problems when providing treatment it is important to use combined medications with fixed pediatric dosages, which would significantly help to simplify the administration of medications and to relieve the psychological, emotional and physical load when taking a significant number of drugs.

Goal of the study: to define the efficiency of using fixed doses of the medication combing 150 mg of isoniazid, 375 mg of pyrazinamide, 150 mg of rifampicin. Clinical, X-ray and laboratory rates were assessed during treatment of 73 children suffering from respiratory tuberculosis, of them 34 children were treated by the medication combing 150 mg of isoniazid, 375 mg of pyrazinamide, 150 mg of rifampicin plus ethambutol, and the other children were treated by the standard chemotherapy. The opportunity of effective use of the medication combining 150 mg of isoniazid, 375 mg of pyrazinamide, 150 mg of rifampicin in children was confirmed by positive results by the completion of the intensive phase of treatment as well as the continuation phase and minimization of adverse reactions during treatment. The combination of active components of the medication and doses is convenient for use, allow conducting directly observed treatment and enhancing the efficiency of chemotherapy.

1. Aksenova V.A. et al. Federal recommendations for diagnostics and treatment of respiratory tuberculosis in children. Med. Alyans, 2015, no. 3, pp. 10-23. (In Russ.)

2. Edict no. 951 by RF MoH as of 29.12.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. (In Russ.) Moscow, 2014, 39 p.

3. Rukovodstvo po lecheniyu tuberkuleza u detey dlya natsionalnykh programm borby s tuberkulezom. [Guidelines on tuberculosis treatment for national TB control program]. 2nd Edition, Chapter 4. (WHO/HTM/TB/13.357d) (In Russ.)

4. Semenova O.V. Otsenka primeneniya mnogokomponentnogo preparata v lechenii bolnykh vpervye vyavlennym tuberkulezom legkikh: Diss. kand. med. nauk. [Evaluation of using multi-component in the treatment of new pulmonary tuberculosis patients. Cand. Diss.]. Moscow, 2003, 139 p.

5. Starshinova А.А. et al. Diagnostic opportunities of modern immunological tests when defining the activity of tuberculous infection in children. Tuberculosis and Lung Diseases, 2012, vol. 89, no. 8, pp. 40-43. (In Russ.)

6. Bangalore S., Kamalakkannan G., Parkar S., Messerli F. Fixed-Dose Combinations Improve Medication Compliance: A meta-analysis. Am. J. Medicine., 2007, vol. 120, issue 8, pp. 713-719.

7. Lienhardt C. at al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for the treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA, 2011, vol. 305, no. 14, pp. 1415-1423.

8. Monedero I., Caminero J. A. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int. J. Tuberc. Lung Dis., 2011, vol. 15, no. 4, pp. 433-439.